OBADEX Research

For a paradigm shift in obesity research

Obesity is associated with chronic metabolic diseases, such as MASH, Type-2 Diabetes and cardiovascular diseases. Despite the emergence of novel effective treatments in recent years, millions of people with obesity remain with no tailored therapeutic solution, in particular patients who are poorly responding to anti-obesity drugs. Stimulating the native beneficial properties of adipose tissue for the regulation of metabolism can pave the way for a comprehensive therapeutic approach for obesity.
In obesity, the balance between white adipose tissue (the ‘bad’ fat) and brown adipose tissue (the ‘good’ fat) is altered, with white adipose tissue accumulating and becoming dysfunctional, while brown adipose tissue disappears or is impaired. Nonetheless, brown adipose tissue is known to burn the excess of energy and regulate metabolism by secreting specific factors preventing chronic metabolic diseases. Stimulating or restoring these natural processes can have a profound impact on obesity management.

A Breakthrough Technology for Chronic Metabolic Disorders and Obesity

ObAdEx is our breakthrough technology that overcomes the barrier of ex vivo culture and production of a viable and metabolically active brown adipose tissue

Our technology allows to transform human white adipose tissue into a functional and metabolically active brown adipose tissue with therapeutic potential. Activation of brown adipose tissue capabilities in patients with obesity might restore the metabolic balance between white and brown adipose tissue, thus preventing and treating chronic metabolic diseases.

ObAdEx has received Deeptech label by BpiFrance and is being developed in collaboration with SATT Sud-Est, CNRS, Nice University Hospital and Côte d’Azur University/Idex.

ObAdEx has received Deeptech label by BpiFrance and is being developed in collaboration with SATT Sud-Est, CNRS, Nice University Hospital and Côte d’Azur University/Idex.




Process scale-up
& industrial adaptation




Clinical batch &
Bridging studies



KOL on adipose tissue biology.

Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice). 

Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program). 

Co-inventor of 5 patents

Expert in clinical applications of adipose tissue.

Plastic Reconstructive and Aesthetic Surgeon in Nice.

Member of the Medical Council of Alpes Maritimes region.

Expert for the French National Regulatory Agency ANSM for medical devices.

Certified by French Health Autority HAS (2020-2024).

PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.

Expert in cell therapy and immunology. 

Senior Lecturer (Maitre de conférences).

Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).

Director of « Micoralis » research team at Université Côte d’Azur (Nice).

Founder and CEO of the biotech company Biointerférence (2003-2006).

Co-inventor of 5 patents.

Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.

With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov. 

In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille). 

He is co-inventor of the 2 company’s patent families. 

Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue. 

Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.

With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years. 

He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.

Main areas of expertise: Biotech Startup Business Development; Project management